Analysts forecast that Kintara Therapeutics, Inc. (NASDAQ:KTRA – Get Rating) will announce earnings per share (EPS) of ($0.11) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Kintara Therapeutics’ earnings, with estimates ranging from ($0.15) to ($0.06). Kintara Therapeutics posted earnings of ($0.23) per share during the same quarter last year, which suggests a positive year over year growth rate of 52.2%. The firm is scheduled to issue its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that Kintara Therapeutics will report full year earnings of ($0.59) per share for the current financial year. For the next financial year, analysts forecast that the firm will post earnings of ($0.55) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover Kintara Therapeutics.
Kintara Therapeutics (NASDAQ:KTRA – Get Rating) last issued its earnings results on Friday, February 11th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.06.
Shares of NASDAQ:KTRA opened at $0.17 on Tuesday. Kintara Therapeutics has a fifty-two week low of $0.14 and a fifty-two week high of $2.85. The business’s fifty day moving average price is $0.33 and its two-hundred day moving average price is $0.50.
Several institutional investors and hedge funds have recently made changes to their positions in KTRA. Virtu Financial LLC increased its stake in Kintara Therapeutics by 371.4% during the 4th quarter. Virtu Financial LLC now owns 64,913 shares of the company’s stock worth $33,000 after acquiring an additional 51,144 shares during the period. Two Sigma Investments LP acquired a new position in Kintara Therapeutics in the third quarter valued at about $47,000. Renaissance Technologies LLC acquired a new stake in Kintara Therapeutics during the fourth quarter worth about $104,000. Citadel Advisors LLC acquired a new position in shares of Kintara Therapeutics in the 4th quarter valued at approximately $127,000. Finally, Advisor Group Holdings Inc. lifted its holdings in shares of Kintara Therapeutics by 182.7% during the 1st quarter. Advisor Group Holdings Inc. now owns 73,367 shares of the company’s stock worth $130,000 after acquiring an additional 47,415 shares during the period. 10.37% of the stock is currently owned by institutional investors.
Kintara Therapeutics Company Profile (Get Rating)
Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer.
- Get a free copy of the StockNews.com research report on Kintara Therapeutics (KTRA)
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.